Wendy Reulman
Physician Assistant · Aliso Viejo, CANPI 1770780462
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 64.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2023 at $17,088 and has fallen 55.5% since, to $7,597 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,240 payments — averaging $43.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Neurocrine Biosciences, Inc.$2K
- UCB, Inc.$1K
- SK Life Science, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Merz Pharmaceuticals, LLC$1K
- plus $13K from 54 others
What the payments were for
- Consulting fees$4,7269%
- Speaking & faculty fees$22,20241%
- Travel & lodging$2,2804%
- Food & beverage$24,41645%
- Education$3211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,945 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 74 | $63,019 |
| UbrelvyUbrogepant | 42 | $51,355 |
| Aimovig AutoinjectorErenumab-Aooe | 54 | $42,762 |
| Nurtec OdtRimegepant Sulfate | 23 | $41,685 |
| VimpatLacosamide | 23 | $27,459 |
| QuliptaAtogepant | 20 | $24,801 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $21,354 |
| Nucynta ErTapentadol Hcl | 11 | $16,966 |
| RytaryCarbidopa/Levodopa | 11 | $16,621 |
| NuvigilArmodafinil | 12 | $13,198 |
| DayvigoLemborexant | 11 | $6,503 |
| Naratriptan Hcl | 77 | $3,017 |
| Zolmitriptan | 17 | $2,275 |
| Duloxetine Hcl | 36 | $1,828 |
| Rivastigmine | 12 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $34,716 | $76,15662 claims |
| PfizerNurtec Odt | $735 | $41,68523 claims |
| UCB, Inc.Vimpat | $1,301 | $27,45923 claims |
| Amneal Pharmaceuticals LLCRytary | $622 | $16,62111 claims |
| Eisai Inc.Dayvigo | $514 | $6,50311 claims |
| Upsher-smith Laboratories LLCTopiramate | $339 | $42834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Aliso Viejo
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
- Asma HussainiThousand Oaks$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.